Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 758-763

  Spina, Edoardo ^a   D'Arrigo, Concetta ^a   Santoro, Vincenza ^a   Muscatello, Maria Rosaria ^a   Pandolfo, Gianluca ^a   Zoccali, Rocco ^a   Diaz, Francisco J ^b   Leon, Jose De ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c EASTERN STATE HOSPITAL   (United States)

Author keywords

Drug interaction; Olanzapine; Pharmacokinetics; Therapeutic drug monitoring; Valproate

Indexed keywords

OLANZAPINE; VALPROIC ACID;

ADULT; ARTICLE; ASTHENIA; BIPOLAR DISORDER; CLINICAL ARTICLE; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SMOKING; SOMNOLENCE; TREATMENT DURATION; TREMOR;

ADULT; AGING; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SMOKING; TIME FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 73849131328     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c0590e     Document Type: Article

References (26)

1. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(Suppl 2): 37-44.
2. Besag FMC, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006;29:95-118.
3. Spina E, de Leon J. Metabolic drug interactions with newer anti-psychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007; 100:4-22.
4. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182-192.
5. Wen X, Wang JS, Kivisto KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52: 547-553.
6. Scheyer RD. Valproic acid: drug interactions. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2002:801-807.
7. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyl-transferases. Biochem Pharmacol. 2003;65:1441-1449.
8. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032-1041.
9. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
10. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233-238.
11. Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuro-Psychopharmacol Biol Psychiatr. 2008;32:1453-1458.
12. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
13. Bergeman N, Kress KR, Abu-Tair F, et al. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol. 2006;26:432-434.
14. D'Arrigo C, Migliardi G, Santoro V, et al. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatogra-phy with ultraviolet detection. Ther Drug Monit. 2006;28:599-602.
15. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. Boca Raton, FL: Chapman & Hall/CRC; 1995.
16. StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP; 2007.
17. Spina E, Avenoso A, Facciolà, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485.
18. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233-238.
19. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994;151:123-125.
20. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994;36:487-488.
21. Facciolà G, Avenoso A, Scordo MG, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999; 21:341-345.
22. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacop-sychiatry. 2008;41:81-91.
23. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21:81-85.
24. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a therapeutic drug monitoring service. J Clin Psychiatry. 2007;68:1540-1545.
25. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. (Pubitemid 39587052)
26. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46:359-388.